Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Similar articles for PubMed (Select 21098469)

1.

The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions.

Lonn E, Bosch J, Teo KK, Pais P, Xavier D, Yusuf S.

Circulation. 2010 Nov 16;122(20):2078-88. doi: 10.1161/CIRCULATIONAHA.109.873232. Review. No abstract available.

2.

Implementation of a simple age-based strategy in the prevention of cardiovascular disease: the Polypill approach.

Wald DS, Wald NJ.

J Eval Clin Pract. 2012 Jun;18(3):612-5. doi: 10.1111/j.1365-2753.2011.01637.x. Epub 2011 Jan 30.

PMID:
21276141
3.

The cardiovascular polypill in high-risk patients.

Lafeber M, Spiering W, Singh K, Guggilla RK, Patil V, Webster R; SPACE collaboration.

Eur J Prev Cardiol. 2012 Dec;19(6):1234-42. doi: 10.1177/1741826711428066. Epub 2011 Oct 21. Review.

PMID:
22019908
4.

Randomized Polypill crossover trial in people aged 50 and over.

Wald DS, Morris JK, Wald NJ.

PLoS One. 2012;7(7):e41297. doi: 10.1371/journal.pone.0041297. Epub 2012 Jul 18.

5.

[Prevention of cardiovascular diseases with multiple risk factors based on "Polypill" concepts].

Guo XY, Zhao D.

Zhonghua Nei Ke Za Zhi. 2010 Nov;49(11):909-11. Chinese. No abstract available.

PMID:
21211200
6.

Polypill strategy for primary prevention of cardiovascular disorders.

Dabhadkar KC, Bellam N.

Drugs Today (Barc). 2013 May;49(5):317-24. doi: 10.1358/dot.2013.49.5.1950148. Review.

PMID:
23724411
7.

Exercise is the real polypill.

Fiuza-Luces C, Garatachea N, Berger NA, Lucia A.

Physiology (Bethesda). 2013 Sep;28(5):330-58. doi: 10.1152/physiol.00019.2013. Review.

8.

Prospects for a cardiovascular disease prevention polypill.

Dabhadkar KC, Kulshreshtha A, Ali MK, Narayan KM.

Annu Rev Public Health. 2011;32:23-38. doi: 10.1146/annurev-publhealth-031210-101214. Review.

PMID:
21219156
9.

Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.

Zomer E, Owen A, Magliano DJ, Ademi Z, Reid CM, Liew D.

Am J Cardiovasc Drugs. 2013 Apr;13(2):121-8. doi: 10.1007/s40256-013-0019-2.

PMID:
23532687
10.

[Cardiovascular polypill in high risk patients].

Lafeber M, Spiering W, Bots ML, de Valk V, Visseren FL, Grobbee DE.

Ned Tijdschr Geneeskd. 2011;155(44):A3070. Review. Dutch.

PMID:
22067559
11.

Requirement of pharmacological treatment for primary prevention of cardiovascular disease in asymptomatic office-executives in north-India.

Kasliwal RR, Bansal M, Mehrotra R, Agrawal V, Shrivastava S.

Indian Heart J. 2010 Jul-Aug;62(4):324-9.

PMID:
21280473
12.

A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.

Soliman EZ, Mendis S, Dissanayake WP, Somasundaram NP, Gunaratne PS, Jayasingne IK, Furberg CD.

Trials. 2011 Jan 5;12:3. doi: 10.1186/1745-6215-12-3.

13.

Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.

Thom S, Field J, Poulter N, Patel A, Prabhakaran D, Stanton A, Grobbee DE, Bots ML, Reddy KS, Cidambi R, Rodgers A.

Eur J Prev Cardiol. 2014 Feb;21(2):252-61. doi: 10.1177/2047487312463278. Epub 2012 Oct 4.

PMID:
23038750
14.

Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges.

Working Group on the Summit on Combination Therapy for CVD, Yusuf S, Attaran A, Bosch J, Joseph P, Lonn E, McCready T, Mente A, Nieuwlaat R, Pais P, Rodgers A, Schwalm JD, Smith R, Teo K, Xavier D.

Eur Heart J. 2014 Feb;35(6):353-64. doi: 10.1093/eurheartj/eht407. Epub 2013 Nov 27. Review.

15.

An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk.

PILL Collaborative Group, Rodgers A, Patel A, Berwanger O, Bots M, Grimm R, Grobbee DE, Jackson R, Neal B, Neaton J, Poulter N, Rafter N, Raju PK, Reddy S, Thom S, Vander Hoorn S, Webster R.

PLoS One. 2011;6(5):e19857. doi: 10.1371/journal.pone.0019857. Epub 2011 May 25.

16.

Polypill: the evidence and the promise.

Lonn E, Yusuf S.

Curr Opin Lipidol. 2009 Dec;20(6):453-9. doi: 10.1097/MOL.0b013e32833305a3. Review.

PMID:
19884824
17.

Polypill: lights and shadows.

Teo KK, Liang Y.

Curr Hypertens Rep. 2010 Aug;12(4):276-81. doi: 10.1007/s11906-010-0127-1. Review.

PMID:
20549577
19.

Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors.

Hennekens CH.

Circulation. 1998 Mar 24;97(11):1095-102. Review. No abstract available. Erratum in: Circulation 1998 May 19;97(19):1995.

20.

The polypill: a potential global solution to cardiovascular disease.

Nguyen C, Cheng-Lai A.

Cardiol Rev. 2013 Jan-Feb;21(1):49-54. doi: 10.1097/CRD.0b013e3182755429. Review.

PMID:
23018668
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk